227 related articles for article (PubMed ID: 12787641)
1. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles.
Avgoustakis K; Beletsi A; Panagi Z; Klepetsanis P; Livaniou E; Evangelatos G; Ithakissios DS
Int J Pharm; 2003 Jun; 259(1-2):115-27. PubMed ID: 12787641
[TBL] [Abstract][Full Text] [Related]
2. Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo.
Duan Y; Sun X; Gong T; Wang Q; Zhang Z
J Mater Sci Mater Med; 2006 Jun; 17(6):509-16. PubMed ID: 16691348
[TBL] [Abstract][Full Text] [Related]
3. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles.
Panagi Z; Beletsi A; Evangelatos G; Livaniou E; Ithakissios DS; Avgoustakis K
Int J Pharm; 2001 Jun; 221(1-2):143-52. PubMed ID: 11397575
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content.
Li M; Panagi Z; Avgoustakis K; Reineke J
Int J Nanomedicine; 2012; 7():1345-56. PubMed ID: 22419876
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers.
Beletsi A; Panagi Z; Avgoustakis K
Int J Pharm; 2005 Jul; 298(1):233-41. PubMed ID: 15936907
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
7. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio.
Mu L; Feng SS
Pharm Res; 2003 Nov; 20(11):1864-72. PubMed ID: 14661934
[TBL] [Abstract][Full Text] [Related]
8. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats.
Li Y; Pei Y; Zhang X; Gu Z; Zhou Z; Yuan W; Zhou J; Zhu J; Gao X
J Control Release; 2001 Apr; 71(2):203-11. PubMed ID: 11274752
[TBL] [Abstract][Full Text] [Related]
9. Design and Development of Bioceramic Based Functionalized PLGA Nanoparticles of Risedronate for Bone Targeting: In-vitro Characterization and Pharmacodynamic Evaluation.
Rawat P; Manglani K; Gupta S; Kalam A; Vohora D; Ahmad FJ; Talegaonkar S
Pharm Res; 2015 Oct; 32(10):3149-58. PubMed ID: 25840949
[TBL] [Abstract][Full Text] [Related]
10. Preferential tumor accumulation and desirable interstitial penetration of poly(lactic-co-glycolic acid) nanoparticles with dual coating of chitosan oligosaccharide and polyethylene glycol-poly(D,L-lactic acid).
Wang G; Chen Y; Wang P; Wang Y; Hong H; Li Y; Qian J; Yuan Y; Yu B; Liu C
Acta Biomater; 2016 Jan; 29():248-260. PubMed ID: 26476340
[TBL] [Abstract][Full Text] [Related]
11. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.
Mittal G; Sahana DK; Bhardwaj V; Ravi Kumar MN
J Control Release; 2007 May; 119(1):77-85. PubMed ID: 17349712
[TBL] [Abstract][Full Text] [Related]
12. Preparation, characterization and uptake of PEG-coated, muco-inert nanoparticles in HGC-27 cells, a mucin-producing, gastric-cancer cell line.
Lin D; Li G; Qin L; Wen Z; Wang J; Sun X
J Biomed Nanotechnol; 2013 Dec; 9(12):2017-23. PubMed ID: 24266257
[TBL] [Abstract][Full Text] [Related]
13. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery.
Avgoustakis K
Curr Drug Deliv; 2004 Oct; 1(4):321-33. PubMed ID: 16305394
[TBL] [Abstract][Full Text] [Related]
14. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties.
Avgoustakis K; Beletsi A; Panagi Z; Klepetsanis P; Karydas AG; Ithakissios DS
J Control Release; 2002 Feb; 79(1-3):123-35. PubMed ID: 11853924
[TBL] [Abstract][Full Text] [Related]
15. PLGA-PEG microspheres of teverelix: influence of polymer type on microsphere characteristics and on teverelix in vitro release.
Mallardé D; Boutignon F; Moine F; Barré E; David S; Touchet H; Ferruti P; Deghenghi R
Int J Pharm; 2003 Aug; 261(1-2):69-80. PubMed ID: 12878396
[TBL] [Abstract][Full Text] [Related]
16. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS.
Mu L; Feng SS
J Control Release; 2003 Jan; 86(1):33-48. PubMed ID: 12490371
[TBL] [Abstract][Full Text] [Related]
17. Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness.
Ishihara T; Kubota T; Choi T; Takahashi M; Ayano E; Kanazawa H; Higaki M
Int J Pharm; 2009 Jun; 375(1-2):148-54. PubMed ID: 19481700
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
19. Long circulating biodegradable poly(phosphazene) nanoparticles surface modified with poly(phosphazene)-poly(ethylene oxide) copolymer.
Vandorpe J; Schacht E; Dunn S; Hawley A; Stolnik S; Davis SS; Garnett MC; Davies MC; Illum L
Biomaterials; 1997 Sep; 18(17):1147-52. PubMed ID: 9259511
[TBL] [Abstract][Full Text] [Related]
20. [Transport of mPEG-PLGA nanoparticles across the rat nasal mucosa].
Wang JT; Lin DH; Qin LF; Wen Z; Guo GP
Yao Xue Xue Bao; 2013 May; 48(5):752-8. PubMed ID: 23888701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
